Plan to seek emergency use nod for Covid-19 antibody therapy

11 March 2021 - 07:38
By Reuters
 Evidence has emerged of
Image: 123RF/Kateryna Kon Evidence has emerged of "profound efficacy" of the therapy. Stock photo.

Vir Biotechnology and Britain's GSK said on Wednesday they planned to seek emergency use authorisation (EUA) for their experimental Covid-19 antibody therapy after interim data from a study showed 85% reduction in hospitalisation and deaths among patients.

An independent panel recommended stopping further enrolment for the late-stage trial due to evidence of “profound efficacy” of the therapy, Vir and GSK said in a joint statement.

Antibody treatments are designed to decrease the severity of Covid-19 among patients diagnosed with the infection.

Additionally, the companies said a new laboratory study showed the therapy, VIR-7831, was equally effective against the UK, SA and Brazilian variants of the coronavirus.

Vir and GSK announced a partnership last year to research Covid-19 treatments.